Timeline of key events in Seattle Genetics
Date | Event | People | Places | Sciences |
---|---|---|---|---|
January 1998 | Seattle Genetics founded | Fell, Siegall | Seattle Genetics | Monoclonal antibodies, Oncology |
1998 | Seattle Genetics licensed patents from Bristol-Myers Squibb | Seattle Genetics | Monoclonal antibodies, Oncology | |
1998 | Seattle Genetics secured its first round of investment | Seattle Genetics | ||
1999 | Seattle Genetics raised $30 million from a number of private investment firms | Seattle Genetics | ||
1999 | Seattle Genetics and Genentech partnership signed | Seattle Genetics, Genentech | Monoclonal antibodies, Oncology | |
2001 | Seattle Genetics began licensing out its technology to other companies | Seattle Genetics | Monoclonal antibodies, Oncology | |
March 2001 | Seattle Genetics raised approximately $51 million through its Initial Public Offering | Seattle Genetics | Monoclonal antibodies | |
2003 | Seattle Genetics launched its clinical trials with brentuximab vedotin | Seattle Genetics | ||
2005 - 2018 | Seattle Genetics discontinued work on 9 drug candidates | Seattle Genetics | ||
2009 | First drug developed by Seattle Genetics, SG40, failed phase IIb trial | Seattle Genetics, Genentech | Monoclonal antibodies, Oncology | |
October 2009 | Genentech ended its drug development partnership with Seattle Genetics | Seattle Genetics, Genentech | Monoclonal antibodies, Oncology | |
December 2009 | Seattle Genetics partnered with Takeda Oncology Company | Seattle Genetics, Takeda | Monoclonal antibodies, Oncology | |
February 2011 | Seattle Genetics submitted a Biologics License Application to the FDA for the approval of brentuximab vedotin | Seattle Genetics | Monoclonal antibodies, Oncology | |
July 2011 | Phase I clinical trials launched for enfortumab vedotin by Seattle Genetics with Agenys/Asterllas Pharma | Seattle Genetics, Astellas Pharma | Monoclonal antibodies, Oncology | |
August 2011 | Seattle Genetics won FDA approval for its first drug - brentuximab vedotin (Adecetris) | Seattle Genetics | Monoclonal antibodies, Oncology | |
February 2017 | FDA granted Breakthrough Therapy designation and Priority Review for polatuzumab vedotin | Seattle Genetics, Genentech | Monoclonal antibodies, Oncology | |
March 2018 | FDA granted drug breakthrough therapy designation to enfortumab vedotin for treating metastatic urothelial cancer | Seattle Genetics, Astellas Pharma | Monoclonal antibodies, Oncology | |
March 2018 | Seattle paid $614.1 million to acquire rights to tucatinib from Cascadian Therapeutics | Seattle Genetics, Cascadian Therapeutics | Oncology | |
July 2018 | Seattle Genetics and Astellas Pharma launched global phase III trials for enfortumab vedotin for treating bladder cancer | Seattle Genetics, Astellas Pharma | Monoclonal antibodies, Oncology | |
June 2019 | Genentech granted FDA approval for polatuzumab vedotin, an antibody drug conjugate developed using Seattle Genetics' technology | Seattle Genetics, Genentech | Monoclonal antibodies, Oncology | |
Jan 1998
Seattle Genetics founded
1998
Seattle Genetics licensed patents from Bristol-Myers Squibb
1998
Seattle Genetics secured its first round of investment
1999
Seattle Genetics raised $30 million from a number of private investment firms
1999
Seattle Genetics and Genentech partnership signed
2001
Seattle Genetics began licensing out its technology to other companies
Mar 2001
Seattle Genetics raised approximately $51 million through its Initial Public Offering
2003
Seattle Genetics launched its clinical trials with brentuximab vedotin
2005 - 2018
Seattle Genetics discontinued work on 9 drug candidates
2009
First drug developed by Seattle Genetics, SG40, failed phase IIb trial
Oct 2009
Genentech ended its drug development partnership with Seattle Genetics
Dec 2009
Seattle Genetics partnered with Takeda Oncology Company
Feb 2011
Seattle Genetics submitted a Biologics License Application to the FDA for the approval of brentuximab vedotin
Jul 2011
Phase I clinical trials launched for enfortumab vedotin by Seattle Genetics with Agenys/Asterllas Pharma
Aug 2011
Seattle Genetics won FDA approval for its first drug - brentuximab vedotin (Adecetris)
Feb 2017
FDA granted Breakthrough Therapy designation and Priority Review for polatuzumab vedotin
Mar 2018
FDA granted drug breakthrough therapy designation to enfortumab vedotin for treating metastatic urothelial cancer
Mar 2018
Seattle paid $614.1 million to acquire rights to tucatinib from Cascadian Therapeutics
Jul 2018
Seattle Genetics and Astellas Pharma launched global phase III trials for enfortumab vedotin for treating bladder cancer
Jun 2019
Genentech granted FDA approval for polatuzumab vedotin, an antibody drug conjugate developed using Seattle Genetics' technology
Respond to or comment on this page on our feeds on Facebook, Instagram or Twitter.